- March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
- October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
- April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
- March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
- October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
- October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Oral S-Nitrosoglutathione Reductase Inhibitor N91115: A Multiple Ascending-Dose Study In Healthy Subjects
- October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Intravenous S-NitrosoglutathioneReductaseInhibitor N6022: An Ascending-Dose Study in Subjects Homozygous for the F508del-CFTRMutation
- October 4, 2014 - Pharmacological Correction and Acute Inhibition of GSNOR Results in Improved In Vitro CFTR Function
- October 4, 2014 - Neutrophil Elastase-Mediated CFTR Damage is Rescued by Intracellular Bioavailable GSNO
- March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
More posters |
October 4, 2014 Neutrophil Elastase-Mediated CFTR Damage is Rescued by Intracellular Bioavailable GSNO
Ramakrishna B. Boyanapalli, Kirsten M. Look, Doug Looker, Peter F. Bove, and Sherif E. Gabriel
Cystic fibrosis (CF) is an autosomal genetic disorder characterized by mutations within the cystic fibrosis transmembrane conductance regulator (CFTR). Within the airways, CF patients suffer from abnormal ion and fluid transport, leading to an increase in mucus accumulation, infection, and inflammation.
As part of the innate immune response, neutrophils migrate into the airways to initially aid in the clearance of infection. However, neutrophils in the lungs of CF patients release neutrophil elastase (NE), a serine protease which has been shown to degrade lung tissue, and specifically target wild type and F508del-CFTR for degradation. More…(1.9MB)
Comments are closed.
|
- January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
- December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
- February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
- January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
- August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
- July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
- April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement
|
